An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.

Autor: Kassim AA; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.; Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University School of Medicine, Nashville, TN., de la Fuente J; Department of Paediatrics, St. Mary's Hospital, Imperial College, London, United Kingdom., Nur E; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands., Wilkerson KL; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.; Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University School of Medicine, Nashville, TN., Alahmari AD; Adult Hematology and Stem Cell Therapy and Cellular Therapy Program, King Faisal Specialist Hospital, Riyadh, Saudi Arabia., Seber A; Pediatric Hematopoietic Stem Cell Transplantation Program, Pediatric Hematopoietic Cell Transplantation, Hospital Samaritano Higienopolis-Americas, São Paulo, Brazil.; Pediatric Hematopoietic Stem Cell Transplantation Program, Pediatric Hematopoietic Cell Transplantation, Instituto de Oncologia Pediatrica-Graacc/Unifesp, São Paulo, Brazil., Bonfim C; Pediatric Bone Marrow Transplantation Program, Hospital Pequeno Príncipe/Instituto de Pesquisa Pele Pequeno Principe, Curitiba, Brazil., Simões BP; Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; Department of Hematology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; Department of Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil., Alzahrani M; Department of Pediatric Hematology/Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Eckrich MJ; Department of Pediatrics, Pediatric Transplant and Cellular Therapy, Wake Forest University School of Medicine, Atrium Health Levine Children's Hospital, Charlotte, NC., Horn B; Department of Pediatrics, Pediatric Bone Marrow Transplant and Cell Therapy Program, University of Florida, Gainesville, FL., Hanna R; Department of Pediatric Hematology/Oncology, Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH., Dhedin N; Department of Hematology, Hematology Adolescents and Young Adults, Saint-Louis Hospital, Paris, France., Rangarajan HG; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH., Gouveia RV; Pediatric Hematopoietic Stem Cell Transplantation Program, Pediatric Hematopoietic Cell Transplantation, Hospital Samaritano Higienopolis-Americas, São Paulo, Brazil.; Pediatric Hematopoietic Stem Cell Transplantation Program, Pediatric Hematopoietic Cell Transplantation, Instituto de Oncologia Pediatrica-Graacc/Unifesp, São Paulo, Brazil., Almohareb F; Adult Hematology and Stem Cell Therapy and Cellular Therapy Program, King Faisal Specialist Hospital, Riyadh, Saudi Arabia., Aljurf M; Adult Hematology and Stem Cell Therapy and Cellular Therapy Program, King Faisal Specialist Hospital, Riyadh, Saudi Arabia., Essa M; Department of Pediatric Hematology/Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Alahmari B; Department of Pediatric Hematology/Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Gatwood K; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN., Connelly JA; Department of Pediatrics, Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN., Dovern E; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Rodeghier M; Rodeghier Consultants, Chicago, IL., DeBaun MR; Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University School of Medicine, Nashville, TN.; Department of Pediatrics, Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN.

Publikováno v: Blood [Blood] 2024 Jun 20; Vol. 143 (25), pp. 2654-2665.

Using novel magnetic resonance imaging methods to predict stroke risk in individuals with sickle cell anemia.

Autor: Jordan LC; Pediatrics-Division of Pediatric Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: lori.jordan@vanderbilt.edu., Kassim AA; Medicine-Division of Hematology/Stem Cell Transplantation, Vanderbilt-Meharry Sickle Cell Center for Excellence, Vanderbilt University Medical Center, Nashville, TN, USA., Wilkerson KL; Medicine-Division of Hematology/Stem Cell Transplantation, Vanderbilt-Meharry Sickle Cell Center for Excellence, Vanderbilt University Medical Center, Nashville, TN, USA., Lee CA; Pediatrics-Division of Pediatric Neurology, Vanderbilt University Medical Center, Nashville, TN, USA., Waddle SL; Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA., Donahue MJ; Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA; Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA; Physics and Astronomy, Vanderbilt University, Nashville, TN, USA.

Publikováno v: Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2020 Jun; Vol. 13 (2), pp. 76-84. Date of Electronic Publication: 2020 Mar 12.

Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.

Autor: Calado RT; Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA. calador@nhlbi.nih.gov, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, Young NS

Publikováno v: Blood [Blood] 2009 Sep 10; Vol. 114 (11), pp. 2236-43. Date of Electronic Publication: 2009 Jun 26.